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ABSTRACT
Background and Aims The proportion of untreated patients with alcohol use disorder (AUD) exceeds that of any other
mental health disorder, and treatment alternatives are needed. Awidely discussed strategy is to depart from the abstinence
paradigm as part of controlled drinking approaches. This first systematic review with meta-analysis aims to assess the ef-
ficacy of non-abstinent treatment strategies compared with abstinence-based strategies.Methods CENTRAL, PubMed,
PsycINFO and Embase databases were searched until February 2019 for controlled (randomized and non-randomized)
clinical trials (RCTs and non-RCTs) among adult AUD populations, including an intervention group aiming at controlled
drinking and a control group aiming for abstinence. Following Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) and Cochrane Collaboration guidelines, literature search, data collection and risk of bias
assessment were carried out independently by two reviewers [International Prospective Register of Systematic Reviews
(PROSPERO), registration no. CRD42019128716]. The primary outcome was the proportion of participants consuming
alcohol at or below the recommended threshold. Secondary outcomes were social functioning, drinking reductions,
abstinence rates and dropouts. Using random-effects models, RCTs and non-RCTs were analyzed separately. Sensitivity
and subgroup analyses accounted for methodological rigor, inclusion of goal-specific treatment, length of follow-up and
AUD severity. Results Twenty-two studies (including five RCTs) with 4204 patients were selected. There was no
statistically significant difference between both treatment paradigms in RCTs [odds ratio (OR) = 1.32, 95% confidence
interval (CI) = 0.51–3.39]. Non-randomized studies of free goal choice favored abstinence-orientation (OR = 0.60,
95% CI = 0.40–0.90), unless goal-specific treatment was provided (OR = 0.79, 95% CI = 0.40–1.56), or in studies
of low risk of bias (OR = 0.73, 95% CI = 0.49–1.09) or with long follow-up (OR = 1.49, 95% CI = 0.78–2.85).
Effect sizes were not clearly dependent upon AUD severity. Abstinence- and controlled drinking interventions did
not clearly differ in their effect on social functioning and drinking reductions. Conclusions Available evidence does
not support abstinence as the only approach in the treatment of alcohol use disorder. Controlled drinking, particularly
if supported by specific psychotherapy, appears to be a viable option where an abstinence-oriented approach is not
applicable.
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INTRODUCTION
Alcohol use disorders (AUD) and alcohol-related harm are
among the most burdensome diseases, both at individual
and at societal levels [1]. With proportions of only approx-
imately 20% of patients receiving treatment, the treatment
gap for AUD exceeds that of any other mental health
disorder [2–4]. This major unmetmedical need, alongwith
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the limited efficacy of treatments applied, is emphasized in
several national treatment guidelines for alcohol-related
disorders [5–7].
Reasons for a lack of successful treatment outcomes
may include the severe nature of AUD, but also the strong
focus on abstinence in current treatment strategies. Given
a somewhat small proportion of patients capable of,
and/or willing to, achieve abstinence [5,8,9], it is imagin-
able that, under an abstinence paradigm, some patients
and clinicians lose confidence in the effectiveness of treat-
ments and are discouraged by the perception that absti-
nence is the only viable goal. In what we sense as a
gradual paradigm-shift in treatment recommendations
in AUD, non-abstinence-oriented treatment options,
namely dose-reduction strategies, have been included as
intermediate treatment goals into the UK National
Institute for Health and Care Excellence (NICE) guidelines
[6] and recommendations by the European Medicine
Agency (EMA) [10]. In addition to pharmaceuticals fos-
tering abstinence (e.g. anti-craving drugs [11]), new
pharmacological approaches, directed at reducing alcohol
consumption (e.g. nalmefene), have been developed and
absence of heavy drinking has now been accepted as an
additional primary outcome for Phase 3 pharmacother-
apy trials of AUD by the US Food and Drug Administra-
tion (FDA) [12].
Since the beginning of the debate on non-abstinent
AUD treatments, ‘controlled drinking (CD)’ has been a con-
troversial term [13]. We pragmatically choose ‘CD’ to gen-
erally specify a treatment goal where patients are aiming
for a sustained pattern of drinking within rationally
pre-defined limits of low-risk consumption. This is beyond
merely striving for ‘moderation’ or ‘reduced drinking’,
and rather than assuming that any AUD patient can re-
turn to such a sustained pattern of drinking we emphasize
that these interventions merely accept CD as a potential
outcome and a valid goal alongside abstinence.
Serious concerns about CD approaches have repeatedly
been put forward, and acceptability among clinicians re-
mains low [14,15]. This applies in particular to
recommending CD as a final rather than intermediate goal,
and to patients with alcohol dependence as opposed to
harmful drinkers [16]. It is feared that CD may be against
the best interests of individuals with AUD, harboring the
risk of self-deception and the risk of undermining treatment
attempts by offering and implementing an alternative to
abstinence treatment, even though the latter is currently
known to be associated with the least risk of harm for the
patient [17,18]. At the same time, a number of clinical tri-
als showed improvements and rates of remission to low-risk
drinking with non-abstinent treatment strategies [19–21].
From a medical viewpoint it is also evident that
drinking reductions decrease the risk of adverse conse-
quences [9,17,22–26].
So far, it is unclear how useful a treatment goal of CD is
relative to approaches aiming for abstinence: trials yielded
contradictory results [19,27] and, in part, are circular,
as defining abstinence as primary outcome favors
abstinence-oriented treatments. The American Psychiatric
Association (APA) has recently emphasized the lack of
evidence regarding the comparison of CD and abstinence
approaches and goal-choice paradigms in general [7]. To
our knowledge, no systematic review including
meta-analysis has been published. The present work is
therefore the most comprehensive attempt aiming to esti-
mate the comparative efficacy of CD approaches in relation
to abstinence paradigms with regard to (1) alcohol
consumption measures as well as (2) drinking-related
and social outcomes, while (3) accounting for
treatment and patient characteristics; namely, disorder
severity, goal-specificity of treatment and definition of
treatment goal.
METHODS
This is a systematic literature review and meta-analysis.
We registered the study protocol on the International
Prospective Register of Systematic Reviews (PROSPERO;
CRD42019128716). Methods followed guidelines by the
Cochrane Collaboration for the conduction of systematic
reviews [28] and the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) [29].
Eligibility criteria: participants, intervention and control
groups
We included prospective follow-up studies comparing the
efficacy of non-abstinent versus abstinent treatment
regimens, using samples of adult patients (≥ 18 years) with
alcohol dependence or alcohol abuse/harmful use
diagnosed according to standard operationalized criteria
(i.e. Research Diagnostic Criteria, DSM-III, DSM-III-R,
DSM-IV, DSM-IV-TR, DSM-5 or ICD-10). All treatment in-
terventions aiming at controlling alcohol consumption
(CD paradigms) on a non-abstinent basis were eligible.
We excluded studies that did not include a comparison
group that aimed for abstinence. Concomitant pharmaco-
logical interventions were not an exclusion criterion, as
long as these were given to both intervention and compar-
ator groups.
Following recommendations by the Cochrane
Collaboration [28], two reviewers independently carried
out the screening of the references retrieved from the
electronic databases (J.H., M.M.), applying the pre-defined
inclusion/exclusion criteria (see above) first by considering
all information provided in title and abstract, and then
reading the full text of relevant studies.
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Outcomes
By definition, intervention and comparison groups are
aiming for different outcomes [abstinence (AB) versus
CD], and outcomes for this study had to reflect both treat-
ment goals. The primary outcomewas defined as the differ-
ence in the probability of achieving CD between the
subjects in the CD-oriented and AB-oriented study arms,
with CD defined as low-risk drinking within recommended
limits (following the study author’s most rigorous defini-
tion), including abstinence. As recommended limits for
low-risk drinking may differ, we decided on adopting the
trial author’s most rigorous, standardized definition that
was most comparable to the National Institute on Alcohol
Abuse and Alcoholism (NIAAA) low-risk (non-binge)
drinking levels [30] and World Health Organization
(WHO) low- or medium-risk drinking levels [31]. This
outcome can be equally reached by both interventions.
However, health benefits may be higher with larger propor-
tions of abstinent patients. In order to present the broader
picture, we defined clinically relevant secondary outcomes,
considering measures of social functioning, measures of al-
cohol consumption and drinking reductions, measures of
abstinence and dropouts.
When a study provided data for more than one mea-
sure of treatment outcome, data for our primary outcome
were considered using the following hierarchy: no drinking
above recommended low-risk limits; no violations of a non-
harmful, low-risk drinking goal (adopting the trial author’s
definition); and controlled, non-harmful drinking days.
Secondary outcomes were defined as: (i) treatment dif-
ference in efficacy on social functioning (considering, in hi-
erarchical order: legal problems, accidents, occupational
status/employment, relationships, inventories of drinking
problems/consequences), (ii) treatment difference in effi-
cacy on substantial improvement in drinking reduction
(adopting the trial author’s definition) and (iii) treatment
differences in number of patients maintaining abstinence
and abstinent days, in rates of subjects with relapse to
heavy drinking and heavy drinking days (HDD), in drinks
per drinking day (DDD) and in dropouts.
Literature search
We searched the Cochrane Central Register of Controlled
Trials (CENTRAL) until 18 February 2019. CENTRAL is fo-
cused upon randomized and non-randomized controlled
studies. It comprises, amongother sources, articles indexed
in MEDLINE, PsycINFO and Embase databases as con-
stantly screened by the Cochrane Drugs and Alcohol
Group (CDAG), following the Cochrane highly sensitive
searches. Additionally, we searched MEDLINE, PsycINFO
and EMBASE from October 2018 onwards, as recom-
mended by the CDAG (personal communication) to identify
studies that could have been missed due to a possible time
lag in CDAG’s screening schedule. In these searches, we
used generic search terms for alcohol-use and
drinking, combined with generic terms for abstinence and
non-abstinent or controlled-drinking approaches (for
explicit search entry, see Supporting information, Fig. S1).
We supplemented the search by carrying out reference
searches of all eligible articles, relevant review articles
and the ‘Mesa Grande Project’ database, which was sys-
tematically updated on clinical trials for AUDs up to 2001
[32,33]. No further restrictions (e.g. for language or time
period) were applied.
Data collection
Two researchers abstracted data from the original studies
(J.H., H.C.). Unclear cases were solved by discussion with
the senior author (C.B.). We retrieved data on the associa-
tion between treatment goal and achieving successful
treatment outcomes [e.g. odds ratio (OR)] or success rates
and total number per group), with respective measures of
statistical dispersion. If a trial provided data for more than
one time-point per outcome, the longest follow-up was in-
cluded for every outcome in our main analyses. For
non-randomized studies, we primarily extracted outcome
data based on a goal choice at study entry, if available. If
data were presented in figures only, values were extracted
using Engauge Digitizer version 11.2 MacOSX (M.
Mitchell). Additionally, information on the following char-
acteristics were retrieved from each of the included studies:
randomization procedure, goal choice and goal-switching
throughout follow-up, treatment intervention and goal-
specificity of treatment, definition of the CD goal,
proportion of patients with alcohol dependence in the
study sample, additional psychopharmacological treat-
ment and the proportions of female and male participants.
Risk of bias assessment
In accordance with the Cochrane Handbook [34],
methodological rigor of studies was assessed using the
Cochrane risk of bias tool for randomized controlled
trials (RCTs) and the Newcastle–Ottawa Scale [35] for
non-randomized studies. Judgments for each study were
duplicated (J.H., H.C.). Additionally, a global rating for each
study was conducted, considering those studies in
the highest third of summary rating scores to be of ‘lower’
risk of bias.
Data analysis
Analyses are based on intention-to-treat (ITT) populations.
If no ITT data were available, we included results on
completer or per-protocol populations, in this order. Study
arms characterized by an imposed goal of abstinence due
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to baseline factors (such as particularly severe AUD)
were excluded from our comparisons (applicable for
Booth et al. [36]).
Summary effect estimates were calculated on the odds
ratio scale [OR and 95% confidence interval (CI)] using
random-effects models (DerSimonian & Laird method) as
the studies differed in several methodological aspects, such
as diagnostic criteria and specific interventions employed.
Effect sizes from different, non-overlapping subgroups
of populations within a study were pooled using a
fixed-effect model, as recommended in the Cochrane
Handbook [34] (three-level meta-analytical approach).
Heterogeneity among studies was quantified with the I2
statistic. An α of 0.05 was considered statistically signifi-
cant for the primary outcome. For all other analysis,
P-values are presented in an exploratory sense. The num-
ber needed to treat (NNT) was calculated for primary out-
come analyses, using success rates of abstinence-oriented
treatment arms as an approximation to the patient’s
expected event rate.
For the primary and the secondary outcomes, RCTs and
non-randomized studies were analyzed separately. For the
primary outcome, non-randomized studies were further
analyzed in three consecutive steps, considering (1) all
non-randomized studies, (2) those presenting data based
on a goal choice of CD within actually defined low risk
limits and (3) those providing goal-specific treatment
intervention.
Sensitivity analyses
For the primary outcome we conducted an additional sen-
sitivity analysis in which, if not otherwise stated or
accounted for within the trial, cases lost to follow-up were
considered as treatment failures (i.e. ‘worst-case analysis’).
Pre-specified subgroup and sensitivity analyses referred
to: studies of higher methodological rigor; studies based on
a CD goal within recommended (low risk) limits (as op-
posed to self-defined reduction or no specific goal at all);
and studies offering goal-specific therapeutic intervention
for patients in each group, respectively. To avoid undue re-
liance upon single trials, in primary outcome sensitivity
analyses we removed all studies one by one from the anal-
ysis (leave-one-out analyses).
Meta-regression and moderator analysis
In random-effects meta-regression for our primary out-
come, we investigated associations of the studies’ effect es-
timates (log OR) with baseline severity of AUD (rating each
study by the proportions of dependent patients and ‘prob-
lem drinkers’/patients with harmful alcohol use), gender
(percentage of female patients) and length of follow-up.
Publication bias
Possible publication bias for the primary outcome analysis
was inspected assessing funnel plot asymmetry using
Egger’s test and by visually inspecting the funnel plot.
Analyses were conducted according to the Cochrane
Collaboration Handbook [28] and using Comprehensive
Meta-Analysis version 3 (Biostat, Engelwood, NJ, USA).
RESULTS
After screening of titles and abstracts of 6134 articles, 123
full texts were assessed for eligibility. Of these, 22 studies,
published between 1973 and 2017, were eligible for sys-
tematic review (Fig. 1). Overall, the studies included
4204 patients, 2251 aiming for abstinence and 1953
aiming for CD. Five studies were RCTs [21,37–40] and
one trial used a partially randomized design [41]. Sixteen
studies allowed patients to choose their goal; eight of these
also allowed for goal-switching during treatment. All five
RCTs and nine of the non-randomized trials provided
goal-specific treatment interventions, i.e. abstinence-
fostering treatment for patients aiming for abstinence and
CD-fostering treatment for patients aiming for CD. The re-
maining trials merely assessed patients’ personal goal but
provided no specific or abstinence-oriented treatment only.
Four studies did not define a goal of CD as aiming for drink-
ing within defined limits and included patients without a
specific goal or those aiming for any drinking reduction
into the CD-oriented groups [19,42–44]. Seven studies in-
cluded patients with alcohol dependence only; the remain-
ing included patients with harmful use in varying degrees.
Four trials included psychopharmacological treatment
[42,44–47]. One study included women only [48] and
one man only [27] (Table 1). Individual definitions of the
primary outcome for each study are presented in
Supporting information, Table S2.
Primary outcome
Defining treatment success as abstinence as well as con-
trolled, low-risk drinking within recommended limits, the
following effect sizes resulted when comparing patients in
abstinence-oriented treatment arms with patients aiming
for CD:
In all following analyses, an OR> 1 favors CD-oriented
study arms.
1. Two RCTs were summarized to an effect size of
OR = 1.32 (95% CI = 0.51–3.39; I2: 0%) (Figure 2).
Quantitatively summarizing all of the five RCTs is im-
possible due to substantial methodological heterogeneity,
and only two provided data suitable for our primary out-
come. However, generally speaking, the remaining three
RCTs showed no statistically significantly stronger effect
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for either treatment approach, but showed point estimates
consistent with better outcomes in CD concerning alcohol
consumption levels [39,40] and the percentage of patients
who reduced their drinking [37]. Differential findings from
all five RCTs are included in our secondary outcome analy-
ses below.
2. (i) Of the non-randomized (observational)
studies assessing goal choice, 12 provided data for
our primary outcome and were summarized to an effect
size of OR = 0.60 (95% CI = 0.40–0.90; I2 = 65.2%)
(Figure 2).
(ii) Among these, 10 studies based analyses on a goal
choice of CD within actually defined low risk limits
(as opposed to no goal or any drinking reduction). These
amounted to OR = 0.68 (95% CI = 0.43–1.08; I2: 60.0%).
(iii) Of these, eight studies provided goal-specific
treatment intervention (i.e. CD-fostering for CD groups
and abstinence-fostering for AB groups), which were
summarized to an effect size of OR = 0.79 (95%
CI = 0.40–1.56; I2: 68.0%).
Risk of bias
Summary ratings of methodological rigor of each study
are presented in Table 1. The non-randomized studies with
the highest ratings [seven of 18, with a score of 6
(range = 4–6)] were considered at a ‘lower’ risk of bias
(Supporting information, Fig. S3).
Subgroup and sensitivity analyses
In all following analyses, an OR > 1 favors CD-oriented
study arms.
Single trials did not greatly influence the calculations as
indicated by leave-one-out analyses.
In all non-randomized studies of higher methodological
rigor (i.e. lower risk of bias), the summary OR was 0.73
(95% CI = 0.49–1.09; I2: 57.7%) (seven studies). Among
non-randomized studies providing goal-specific treatment
intervention, those at lower risk of bias were summarized
to an OR of 0.98 (95% CI = 0.44–2.20, I2: 69,7%) (five
studies).
Broken down by group, and based on ‘worst-case’
analyses, 44.1% (95% CI = 30.3–58.9%) of abstinence-
oriented patients and 34.0% (95% CI = 25.7–43.3%) of
CD-oriented patients successfully exercised low-risk
drinking (13 studies). Taking into account studies that
defined a CD goal within limits and provided goal-specific
interventions, success rates amounted to 39.9% (95%
CI = 24.7–57.2%) for abstinence-oriented patients and
36.1% (95% CI = 28.5–44.4%) for CD-oriented patients.
Among non-randomized studies of higher methodological
rigor (low RoB only) providing goal-specific treatment
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow-chart
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intervention, success rates were: 37.6% (95% CI =
13.0–70.9%) of abstinence-oriented patients and 39.2%
(95% CI = 33.8–44.9%) of CD-oriented patients.
Meta-regressions and moderator analyses
Length of follow-up
Meta-regression among studies (n = 14) providing
outcome data for subsequent lengths of follow-up yielded
a statistically significant decrease in differences between
abstinence-orientation and CD-approaches over time
(primary outcome), and effect sizes tended in favor of
controlled drinking approaches with longer follow-up
(statistically significant correlation [slope = 0.0428;
degrees of freedom (d.f.) = 1; P-value (two-sided) = 0.0204;
R2 = 0.25] between effect size and length of follow-up
(Supporting information, Fig. S4). Among investigations
of follow-up periods of more than 12 months (i.e.
24–42 months), the summary OR was 1.49 (95%
CI = 0.78–2.85; I2: 0%) (four studies). No interaction be-
tween length of follow-up and AUD severity at baseline
was observed. Attrition rates were not substantially differ-
ent between studies of shorter and longer follow-up.
AUD severity at baseline
In trials including patients with alcohol dependence only,
goal choices did not differ statistically significantly in our
primary outcome: OR = 0.61 (95% CI = 0.29–1.27; I2:
68.9%) (five studies). Similarly, meta-regression of our pri-
mary outcome analysis did not indicate interaction of effect
size and AUD severity (Supporting information, Fig. S5).
Gender
Gender distribution in primary studies (as measured in
percentage of female patients per study population) did
not affect effect size (Supporting information, Fig. S6).
Numerical results from primary outcomes, subgroup
and sensitivity analyses are summarized in Table 2.
Secondary outcomes
All secondary outcomes are presented in Fig. 3.
i In abstinence- and CD-oriented studyarms,measures of
social functioning improved equally.
ii Equal proportions of patients achieved substantial
improvement in drinking reduction. Broken down by
group, 58.8% (95% CI = 51.2–65.9%) of abstinence-
oriented patients and 58.3% (95% CI = 51.1–64.2%)
of CD-oriented patients substantially improved regard-
ing drinking severity.
iii Briefly, there were no clear-cut differences
between abstinence-oriented and controlled drinking
approaches. Dropouts tended to occur more frequently
in abstinence arms whereas abstinence was observed
more often, but not exclusively, in abstinence arms.
By group, 21.2% (95% CI = 15.5–28.3%) of
abstinence-oriented patients and 9.7% (95%
CI = 5.9–15.4%) of CD-oriented patients maintained
abstinence at follow-up.
Publication bias
Regarding indication of small study effects, there was no
obvious funnel plot asymmetry upon visual inspection
and using Egger’s test (P = 0.462; two-tailed) (Supporting
information, Fig. S7).
DISCUSSION
Our analyses yielded the following main results. (a) With
regard to controlled, low-risk use of alcohol, there was no
statistically significant difference between abstinence- and
CD-oriented approaches, based on data from the limited
number of small RCTs. (2) In non-randomized studies ana-
lyzing free goal-choice behavior, no statistically significant
difference was found when patients received goal-specific
treatment interventions and the two approaches were ob-
served to be of equal efficacy in the limited number of stud-
ies of higher methodological quality. With no specific or
Figure 2 Forest plot, primary outcome (separate document)
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abstinence-based treatment intervention only, however,
patients were more likely to achieve low-risk drinking
when aiming for abstinence. (3) Results on social parame-
ters, improvements in drinking severity, relapse into heavy
drinking and drinks per drinking day indicated equal effi-
cacy of either treatment modality. Additional findings sug-
gest that achieving controlled, low-risk drinking is more
likely when patients aim for drinking within recom-
mended, low-risk limits than when they follow a
self-defined reduction. Effect sizes in observational trials
were dependent upon length of follow-up and
CD-oriented treatment were more effective in studies with
a follow-up of 2 years and longer.
Implications
While one obvious inference of this investigation is the
pressing need for high-quality RCTs in the future, clini-
cians and patients are currently facing clinical decision
uncertainty regarding abstinence versus CD in the man-
agement of AUD. How can our results inform these
decisions?
Our findings provide evidence to address some of the
concerns that have been raised against the CD paradigm.
First, our results indicate that offering a goal of CD does
not undermine patients’ insight into necessary changes
in behavior per se, as one-third of patients returning to
low-risk drinking in CD-oriented arms maintained absti-
nence. More generally, a substantial proportion of individ-
uals initially choosing CD switched to a goal of abstinence
in trials allowing for realignment. Accordingly, with CD,
patients seem to be open to proposals for change and previ-
ous work has found that patient participation in drinking
goal choice increases goal commitment and self-efficacy
[56], and goal acceptance seems to be correlated to a pos-
itive outcome [57]. Secondly, there is no indication from
our meta-regression that severity of AUD predicts whether
a patient will do better under an abstinence-oriented or a
CD treatment regimen, as the results did not change be-
tween patients with alcohol dependence and hazardous/
harmful drinkers. Therefore, our results do not confirm
the conventional wisdom that CD is only acceptable in
non-dependent patients.
In general, neither RCTs nor observational studies
provide clear-cut support for a focus on abstinence- or
CD-oriented treatment approaches. Wide CIs, contradic-
tory signals from summary effects, substantive heterogene-
ity in several of our analyses, as well as only few and dated
Table 2 Numerical results—primary outcomes, subgroup and sensitivity analyses.
Primary outcome
OR 95% CI P I2 (%) In favor of NNT n studies
RCT 1.32 0.51–3.39 0.57 0 CD 14 2
Non-RCT 0.60 0.40–0.90 0.013 65.2 AB 8 12
CD goal within defined low-risk limits 0.68 0.43–1.08 0.099 60.0 AB 11 10
Goal-specific treatment intervention,
CD goal within low-risk limits
0.79 0.40–1.56 0.492 68.0 AB 19 8
Subgroup and sensitivity
analyses
Low risk of bias (non-RCT) 0.73 0.49–1.09 0.119 57.7 AB 15 7
goal-specific treatment intervention,
low risk of bias (non-RCT)
0.98 0.44–2.20 0.967 69.7 AB 212 5
Alcohol-dependent patients only 0.61 0.29–1.27 0.183 68.9 AB 8 5
Follow-up 24–42 months 1.49 0.78–2.85 0.224 0 CD 12 4
Per group analyses









Worst case analysis 44.1% 30.3%–58.9% 34.0% 25.7%–43.3% AB 9 13
CD goal within low-risk limits,
goal-specific treatment intervention
39.9% 24.7%–57.2% 36.1% 28.5%–44.4% AB 16 9
Goal-specific treatment intervention,
low risk of bias (non-RCT)
37.6% 13.0%–70.9% 39.2% 33.8%–44.9% CD 63 4
RCT = randomized controlled trial; OR = odds ratio; CI = confidence interval; NNT = number needed to treat; AB = abstinence; CD = controlled drinking.
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RCTs, mean that the case is still open as to whether CD or
abstinence-orientation are similar in efficacy.
Certainly, more often than not, abstinence is desirable
from a medical point of view [17] and, clearly, patients
are more likely to maintain abstinence with AB-oriented
interventions. Even beyond that, our ‘worst-case scenario’
analysis indicates that a larger proportion of patients will
achieve controlled, low-risk drinking with a goal of absti-
nence (44% as opposed to 34% in CD-oriented arms). This
analysis, however, entails patients in CD-oriented arms
whowere not aiming for low-risk drinking or whowere of-
fered no or abstinence-oriented treatments only, and 95%
CIs were overlapping. The more patients are provided with
a goal-specific treatment, themore CD orientation becomes
a similarly effective approach. Nevertheless, 34% may be
regarded a sizeable success rate in CD arms with respect
to the current low treatment rates in AUD. Even beyond
that, if low-risk drinking levels are not achieved, numeri-
cally equal proportions of patients in AB- and CD-goal
treatment arms will benefit from treatments by improve-
ments in drinking severity. Consistent with our findings,
accumulating evidence confirms the achievability of
non-abstinent recovery and—importantly—the associated
improvements in physical and mental health [26], mortal-
ity [17], psychiatric comorbidity and quality of life [58,59]
and social functioning [60,61]. Our findings seem particu-
larly relevant to the field, given the low acceptability of
non-abstinent treatment goals among clinicians in several
countries [14,15,62,63].
The unsatisfactory success of current
abstinence-oriented treatments points to the need for re-
finement of, or alternatives to, such approaches. Our re-
sults suggest that CD, when accompanied by CD-fostering
treatment intervention, is not inferior. In light of the re-
maining uncertainty and the experience in the field with
the abstinence paradigm, CD may be seen as an option af-
ter abstinence has not been achieved or if patients are not
at all willing to stop drinking altogether.
Strengths and limitations
This study has several strengths, but it is also not without
limitations. First, selection bias is unlikely to have affected
our review, as our search strategy followed the recommen-
dations by the CDAG, and beyond database screening we
searched reference lists of reviews and previous systematic
search efforts (e.g. ‘Mesa Grande Project’). We must ac-
knowledge, however, the potential for studies to have been
missed. Secondly, all steps of this review were duplicated,
following best-practicemethods.We also put substantial ef-
fort into contacting authors of relevant studies and re-
ceived an unusual amount of feedback, including
previously unpublished data. As a result, to our knowledge,
this is the most comprehensive review on the topic to date.
Thirdly, choice of the primaryoutcomewas a challenge. Al-
though reasonably pragmatic, it may still be slightly biased
against abstinence strategies, because there may be more
health benefit in groups with higher proportions of absti-
nent patients. Therefore, only with our secondary outcome
analyses, we believe that our analyses present the full pic-
ture. Fourthly, our conclusions are limited by the limita-
tions of primary studies. Many of them, especially the
RCTs, date back more than 30 years. Several studies car-
ried a high risk of bias, particularly non-randomized stud-
ies. Those trials, however, allow an approximation of the
effect of goal-choice in a naturalistic setting and offer the
Figure 3 Secondary outcomes (separate document)
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opportunity to study treatment details in a
hypothesis-generating fashion. Fifthly, our analyses include
patients with various degrees of severity of AUD.
Meta-regression and moderator analyses, however, ad-
justed for illness severity, because high disorder severity
has been discussed as a contraindication to controlled
drinking. Interestingly, this was not confirmed by our
findings. Sixthly, we found moderate to substantial
between-study heterogeneity in our main analysis (except
for RCTs). Therefore, we used random effects, carried out
numerous sensitivity and subgroup analyses of more ho-
mogeneous samples and verified the robustness of results
after leaving each study out. Even beyond that, our
meta-regressions and moderator analyses pointed to the
robustness of our findings. Seventhly, declining differences
in efficacy with longer follow-up may be caused by higher
dropout-rates in both treatment arms over time, resulting
in decreased relative effect sizes between the two para-
digms. Reassuringly, however, dropout rates were not sub-
stantially different between studies of longer and those of
shorter follow-up.
Conclusions
The present evidence does not unequivocally favor
abstinence-based approaches in the treatment of AUDs.
In fact, the few, and methodologically limited, RCTs point
to equal efficacy of either strategy. While summary effects
of non-randomized controlled trials tended to favor
abstinence-based approaches in the short term,
CD-orientation proved to be non-inferior with specific
treatment intervention, with ongoing follow-up and in
studies of higher methodological rigor. The results, how-
ever, are marked by wide CIs and heterogeneity, indicating
a need for sufficiently powered RCTs to guide clinical deci-
sion making. For now, CD, particularly if accompanied by
specific psychotherapy support, seems to be a viable option
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